GT200000169A - Procedimiento para la preparacion de compuesto de pirazolo [4, 3 - d] pirimidin -7-onas-3-piridilsulfonilo eintermedios de los mismos. - Google Patents

Procedimiento para la preparacion de compuesto de pirazolo [4, 3 - d] pirimidin -7-onas-3-piridilsulfonilo eintermedios de los mismos.

Info

Publication number
GT200000169A
GT200000169A GT200000169A GT200000169A GT200000169A GT 200000169 A GT200000169 A GT 200000169A GT 200000169 A GT200000169 A GT 200000169A GT 200000169 A GT200000169 A GT 200000169A GT 200000169 A GT200000169 A GT 200000169A
Authority
GT
Guatemala
Prior art keywords
piridilsulfonilo
eintermedios
pirazolo
pirimidin
onas
Prior art date
Application number
GT200000169A
Other languages
English (en)
Inventor
Keith Michael Devries
Philip Charles Levett
Joanna Teresa Negri
Albert Shaw Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924042.6A external-priority patent/GB9924042D0/en
Priority claimed from GB0018667A external-priority patent/GB0018667D0/en
Application filed filed Critical
Publication of GT200000169A publication Critical patent/GT200000169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA SINTESIS DE: 1ETIL4[5(3ETIL6,7DIHIDRO7OXO2(2PIRIDILMETIL) 2HPIRAZOLO [4,3D]PIRIMIDIN5IL ]6(2METOXIETOXI)3PIRIDILSULFONIL] PIPERAZINA (FORMULA IA), MEDIANTE LA REACCION DEL COMPUESTO (IIA) O (IIIA). VER FORMULA IA, IIA Y IIIA. LA INVENCION SE REFIERE OBJETIVAMENTE, NO SOLO A LA FABRICACION, AISLAMIENTO, CARACTERIZACION Y DETERMINACION DE SUS PROPIEDADES FARMACEUTICAS SINO TAMBIEN AL SUMINISTRO DE SUS SALES FARMACEUTICAMENTE ACEPTABLES EN SUS FORMAS DE DOSIFICACION SOLIDAS Y ESTABLES; TALES FORMULACIONES COMPRENDEN COMPRIMIDOS ORALES DE LIBERACION CONTROLADA EN DIFERENTES PRESENTACIONES. EL COMPUESTO DE LA INVENCION TAMBIEN PUEDE ADMINISTRARSE POR VIA PARENTERAL EN SOLUCIONES ACUOSAS ESTERILES, POR VIA INTRANASAL EN FORMA DE POLVO. EN OTRO ASPECTO DE LA INVENCION EL COMPUESTO ES UTIL PARA EL TRATAMIENTO CURATIVO O PROFILACTICO DE UNA AFECCION PARA LO QUE ESTA INDICADO UN INHIBIDOR DE LA PDE5 DE GMPC. ENTRE ELLAS DISFUNCION ERECTIL, IMPOTENCIA, PARTO PREMATURO, DISMINORREA, INCONTINENCIA, ENFERMEDAD DE LAS ARTERIAS CORONARIAS, HIPERTENSION, APOPLEJIA, RINITIS, ASMA ALERGICA Y OTRAS.
GT200000169A 1999-10-11 2000-10-10 Procedimiento para la preparacion de compuesto de pirazolo [4, 3 - d] pirimidin -7-onas-3-piridilsulfonilo eintermedios de los mismos. GT200000169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924042.6A GB9924042D0 (en) 1999-10-11 1999-10-11 Process for thr preparation of pyrazolo[4,3-D]pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof
GB0018667A GB0018667D0 (en) 2000-07-28 2000-07-28 Process for the preparation of pyrazolo [4,3-d] Pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof

Publications (1)

Publication Number Publication Date
GT200000169A true GT200000169A (es) 2002-04-03

Family

ID=26244761

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000169A GT200000169A (es) 1999-10-11 2000-10-10 Procedimiento para la preparacion de compuesto de pirazolo [4, 3 - d] pirimidin -7-onas-3-piridilsulfonilo eintermedios de los mismos.

Country Status (39)

Country Link
EP (1) EP1092720B1 (es)
JP (1) JP2001114783A (es)
KR (1) KR100395718B1 (es)
CN (1) CN1292379A (es)
AR (1) AR029767A1 (es)
AT (1) ATE286899T1 (es)
AU (1) AU6543600A (es)
BG (1) BG104840A (es)
BR (1) BR0004787A (es)
CA (1) CA2322995A1 (es)
CO (1) CO5251476A1 (es)
CZ (1) CZ20003754A3 (es)
DE (1) DE60017330D1 (es)
DZ (1) DZ3096A1 (es)
EA (1) EA003145B1 (es)
EE (1) EE200000537A (es)
EG (1) EG22775A (es)
GT (1) GT200000169A (es)
HR (1) HRP20000674A2 (es)
HU (1) HUP0003979A3 (es)
ID (1) ID27539A (es)
IL (1) IL138913A0 (es)
IN (1) IN190477B (es)
IS (1) IS5654A (es)
MA (1) MA25867A1 (es)
MX (1) MXPA00009936A (es)
NO (1) NO316072B1 (es)
NZ (1) NZ507431A (es)
OA (1) OA11495A (es)
PA (1) PA8504601A1 (es)
PE (1) PE20010682A1 (es)
PL (1) PL343140A1 (es)
SG (1) SG97950A1 (es)
SK (1) SK15052000A3 (es)
SV (1) SV2002000194A (es)
TN (1) TNSN00195A1 (es)
TR (1) TR200002959A2 (es)
UY (1) UY26388A1 (es)
YU (1) YU59100A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
CN101309903B (zh) * 2005-11-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 制备thoc的新方法
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
SG192576A1 (en) * 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EP4001266A3 (en) * 2016-11-21 2022-10-12 Adama Agan Ltd. Process for preparing methoxy methyl pyridine dicarboxylate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ338075A (en) * 1997-04-25 2000-10-27 Pfizer Ltd Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction
CA2329077C (en) * 1998-04-20 2007-09-18 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera

Also Published As

Publication number Publication date
EP1092720A3 (en) 2001-09-19
IL138913A0 (en) 2001-11-25
DE60017330D1 (de) 2005-02-17
AU6543600A (en) 2001-04-12
HUP0003979A3 (en) 2002-03-28
SG97950A1 (en) 2003-08-20
TNSN00195A1 (fr) 2005-11-10
MA25867A1 (fr) 2003-10-01
SK15052000A3 (sk) 2003-01-09
EP1092720B1 (en) 2005-01-12
HU0003979D0 (en) 2000-12-28
CA2322995A1 (en) 2001-04-11
PL343140A1 (en) 2001-04-23
NO20005104L (no) 2001-04-17
EP1092720A2 (en) 2001-04-18
MXPA00009936A (es) 2002-10-23
EA200000924A2 (ru) 2001-04-23
BR0004787A (pt) 2001-05-22
NZ507431A (en) 2002-09-27
CN1292379A (zh) 2001-04-25
YU59100A (sh) 2003-10-31
HUP0003979A2 (hu) 2001-12-28
BG104840A (bg) 2001-10-31
JP2001114783A (ja) 2001-04-24
UY26388A1 (es) 2001-05-31
NO20005104D0 (no) 2000-10-10
OA11495A (en) 2004-05-05
AR029767A1 (es) 2003-07-16
DZ3096A1 (fr) 2004-06-20
HRP20000674A2 (en) 2001-08-31
TR200002959A2 (tr) 2001-07-23
IS5654A (is) 2001-04-12
EG22775A (en) 2003-08-31
NO316072B1 (no) 2003-12-08
PA8504601A1 (es) 2002-02-21
IN190477B (es) 2003-08-02
EA003145B1 (ru) 2003-02-27
ID27539A (id) 2001-04-12
EA200000924A3 (ru) 2001-06-25
KR100395718B1 (ko) 2003-08-25
PE20010682A1 (es) 2001-07-04
SV2002000194A (es) 2002-01-23
KR20010050935A (ko) 2001-06-25
EE200000537A (et) 2001-06-15
ATE286899T1 (de) 2005-01-15
CO5251476A1 (es) 2003-02-28
CZ20003754A3 (cs) 2002-06-12

Similar Documents

Publication Publication Date Title
GT200000170A (es) Agentes terapeuticos.
GT200000168A (es) Compuestos farmaceuticamente activos.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR8859A (es) Derivados de piridina
UY26782A1 (es) Derivados del benzotiazol
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PA8503501A1 (es) Derivados de purina
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
PA8528501A1 (es) Derivados de purina
PA8511801A1 (es) Derivados de purina
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
UY29893A1 (es) Derivados de pirazina
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
GT200000169A (es) Procedimiento para la preparacion de compuesto de pirazolo [4, 3 - d] pirimidin -7-onas-3-piridilsulfonilo eintermedios de los mismos.
TW200800984A (en) New compounds
CY1108785T1 (el) Σταθερη φαρμακευτικη γελη diclofenac na
AR024411A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas.